The effect of Suvorexant for migraine attack suppressio

Not Applicable

Recruiting

• Conditions: migraine

• Registration Number: JPRN-UMIN000019822
• Lead Sponsor: Tokai University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Less than 19 years old Patients who have got serious adverse events by suvorexant CYP3A inhibitors Narcolepsy, Catalepsy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The evaluation items * The degree of sleepless serious illness by the suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) Evaluation schedule * The degree of sleepless serious illness before suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * The degree of sleepless serious illness for the 1st week after suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * 1 month later of suvorexant internal use, the degree of sleepless serious illness (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * 3 months later of suvorexant internal use, the degree of sleepless serious illness (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS)